Technical Analysis for SLRN - Acelyrin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 3.71% | |
| Hot IPO Pullback | Bullish Swing Setup | 3.71% | |
| Doji - Bullish? | Reversal | 3.71% | |
| New 52 Week Low | Weakness | 3.71% | |
| Outside Day | Range Expansion | 3.71% | |
| Wide Bands | Range Expansion | 3.71% | |
| Oversold Stochastic | Weakness | 3.71% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Hot IPO Pullback Entry | about 11 hours ago |
| Rose Above Previous Day's High | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 12 hours ago |
| Up 3% | about 14 hours ago |
| 1.5x Volume Pace | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.84 |
| 52 Week Low | 16.6 |
| Average Volume | 715,673 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 19.97 |
| 10-Day Moving Average | 17.96 |
| Average True Range | 1.58 |
| RSI (14) | 32.43 |
| ADX | 0.0 |
| +DI | 9.45 |
| -DI | 25.99 |
| Chandelier Exit (Long, 3 ATRs) | 21.10 |
| Chandelier Exit (Short, 3 ATRs) | 21.34 |
| Upper Bollinger Bands | 24.60 |
| Lower Bollinger Band | 15.34 |
| Percent B (%b) | 0.24 |
| BandWidth | 46.36 |
| MACD Line | -2.16 |
| MACD Signal Line | -1.61 |
| MACD Histogram | -0.5444 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.92 | ||||
| Resistance 3 (R3) | 18.82 | 18.28 | 18.70 | ||
| Resistance 2 (R2) | 18.28 | 17.94 | 18.33 | 18.63 | |
| Resistance 1 (R1) | 17.94 | 17.74 | 18.11 | 18.04 | 18.55 |
| Pivot Point | 17.40 | 17.40 | 17.49 | 17.45 | 17.40 |
| Support 1 (S1) | 17.06 | 17.06 | 17.23 | 17.16 | 16.65 |
| Support 2 (S2) | 16.52 | 16.86 | 16.57 | 16.57 | |
| Support 3 (S3) | 16.18 | 16.52 | 16.50 | ||
| Support 4 (S4) | 16.28 |
